41 min
John Wilcox (S3BONUS) Entrepreneurial Insights
-
- Entrepreneurship
On his ninth birthday, John Wilcox was diagnosed with Type 1 diabetes. These days, he’s looking to help others with the same health condition. Wilcox is the CEO and cofounder of Diatech Diabetes, a local medical device startup that’s developing a software platform to help people with diabetes obtain proper amounts of insulin.
There are about 600,000 diabetes patients who use insulin pumps in the U.S. They regularly inject insulin into their body, ideally ensuring that they receive the correct amount of insulin. The margin for error is high, though, and malfunctions happen frequently.
Diatech’s software is set to study data in an insulin pump’s system to make analyses and predictions while also providing alarms when a pump is malfunctioning and insulin dosages aren’t right. The startup plans to sell the software to insulin pump manufacturers, and the company is operating on a flexible, two-year timeline. It wants to complete clinical studies and form a strong relationship with a pump manufacturer by 2023 or 2024.
Already, it’s scored a $300,000 grant from the National Institutes of Health. And in November 2021, Diatech won The Next Big Thing – an annual pitch competition hosted by The Society of Entrepreneurs and Epicenter – which came with a $10,000 prize.
Links to items mentioned in the interview:
Diatech Diabetes
Epicenter Memphis
UMRF Research Park
Memphis Business Journal
JDRF
American Diabetes Association
On his ninth birthday, John Wilcox was diagnosed with Type 1 diabetes. These days, he’s looking to help others with the same health condition. Wilcox is the CEO and cofounder of Diatech Diabetes, a local medical device startup that’s developing a software platform to help people with diabetes obtain proper amounts of insulin.
There are about 600,000 diabetes patients who use insulin pumps in the U.S. They regularly inject insulin into their body, ideally ensuring that they receive the correct amount of insulin. The margin for error is high, though, and malfunctions happen frequently.
Diatech’s software is set to study data in an insulin pump’s system to make analyses and predictions while also providing alarms when a pump is malfunctioning and insulin dosages aren’t right. The startup plans to sell the software to insulin pump manufacturers, and the company is operating on a flexible, two-year timeline. It wants to complete clinical studies and form a strong relationship with a pump manufacturer by 2023 or 2024.
Already, it’s scored a $300,000 grant from the National Institutes of Health. And in November 2021, Diatech won The Next Big Thing – an annual pitch competition hosted by The Society of Entrepreneurs and Epicenter – which came with a $10,000 prize.
Links to items mentioned in the interview:
Diatech Diabetes
Epicenter Memphis
UMRF Research Park
Memphis Business Journal
JDRF
American Diabetes Association
41 min